Brain Changes in Fear

  • STATUS
    Recruiting
  • End date
    Sep 30, 2029
  • participants needed
    1872
  • sponsor
    National Institute of Mental Health (NIMH)
Updated on 21 June 2021
depression
anxiety
depressive disorder
specific phobia
traumatic stress disorder

Summary

The purpose of this study is to use brain imaging technology to investigate brain changes in people exposed to predictable versus unpredictable unpleasant stimuli. Unpleasant events that can be predicted evoke a response of fear, whereas unpredictable, unpleasant stimuli cause chronic anxiety not associated with a specific event. Information gained from this study may help in the development of more effective treatments for anxiety disorders.

When confronted with fearful events, people eventually develop fear of specific cues that were associated with these events as well as to the environmental context in which the fearful event occurred. Evidence suggests that cued fear and contextual fear model different aspects of anxiety. However, studies that examine the way the brain affects expression of contextual fear have not been conducted. This study will use magnetic resonance imaging (MRI) or Magneto-encephalography (MEG) to compare the brain activity underlying fear brought on by predictable and unpredictable aversive stimuli.

Description

This protocol examines the neurobiology of fear and anxiety using various approaches. During fear conditioning in which a phasic explicit cue (e.g., a light) is repeatedly associated with an aversive unconditioned stimulus (e.g., a shock), the organism develops fear to the explicit cue as well as to the environmental context in which the experiment took place. Experimental evidence suggests that cued fear and contextual fear model different aspects of anxiety. Studies in patients indicated that contextual fear may model an aspect that is especially relevant to anxiety disorders. However, the neural basis for the expression of contextual fear has not previously been elucidated in human imaging studies.

One important determinant of contextual fear is predictability: contextual fear increases when a threat (e.g., electric shock) is unpredictable, as opposed to when the threat is predictable. The aim of this study is to compare the neural substrates underlying fear evoked by predictable versus unpredictable shocks. Animal studies have indicated that conditioned responses to predictably cued threat and to less explicit threat are separate processes mediated by distinct brain structures. Psychophysiological data suggest that the proposed procedure can differentiate between these two responses. Hence, we anticipate that this procedure will allow us to compare brain correlates of these responses in humans.

Another objective is to study effects of threat of shock on processing and learning of threat cues in the amygdala, the visual and auditory systems, and motivation/reward systems. This will be investigated by means of event-related magneto-encephalography (MEG) and fMRI measurements using various paradigms.

Finally, a last project will examine how pharmacologic manipulation of gamma-aminobutyric acid (GABA) levels with the benzodiazepine alprazolam affects the relationship between GABA concentration (quantified with magnetic resonance spectroscopy, MRS), visual-and auditory-induced gamma oscillations (measured with MEG), and fMRI BOLD response.

Details
Condition Fear, ANXIETY NEUROSIS, Anxiety Disorders (Pediatric), Generalized Anxiety Disorder (GAD), Generalized Anxiety Disorder (GAD - Pediatric), Anxiety Disorders, anxiety disorder
Treatment Acoustic startle, Shock device
Clinical Study IdentifierNCT00047853
SponsorNational Institute of Mental Health (NIMH)
Last Modified on21 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

All screening procedures described in this section are conducted under
screening protocol 01-M-0254. Subjects must meet the following inclusion
criteria in order to participate in the study
Male or female volunteers ages 18-50 years old
Judged to be in good physical health on the basis of medical history, a clinical MRI scan, and physical examination. Physical exams will be conducted by a NIMH credentialed physician or nurse. Clinical laboratory tests will be ordered based on his/her discretion
Healthy subjects judged to be in good psychiatric health on the basis of the Structured Clinical Interview for DSM-IV-TR. The SCID will be administered by a credentialed NIMH clinician
Able to understand procedures and agree to participate in the study by giving written informed consent
This protocol (02-M-0321) will include patients with a primary diagnosis (under the clinical responsibility of Dr. Daniel Pine) of generalized anxiety disorder, panic disorder, SAD, PTSD, specific phobia, and major depression according to DSM-IV
Subjects will not be asked to completely stop smoking or drinking coffee during this study because they may experience withdrawal symptoms, which could affect our study results. However, they will be asked to abstain from drinking caffeinated beverage including coffee, tea and caffeinated soft drinks and from smoking for at least 1 hour prior to testing. They will also be instructed not to drink alcohol on the night prior to testing and on the day of testing
Speaks English or Spanish fluently (subjects with Major Depressive Disorder, healthy volunteers)
Speaks English fluently (subjects with Anxiety Disorder)

Exclusion Criteria

Subjects will be excluded from the study if they meet the following exclusion
criteria
Clinically significant organic disease, e.g., cardiovascular disease
Clinically significant abnormalities in physical examination
Any medical condition that increases risk for fMRI (e.g. pacemaker, metallic foreign body in eye)
History of any disease, which in the investigators opinion may confound the results of the study, including, but not limited to, history of organic mental disorders, seizure, or mental retardation
Have a current diagnosis of alcohol or substance abuse ACCORDING TO DSM IV CRITERIA
Have a lifetime diagnosis of alcohol or substance dependence ACCORDING TO DSM IV CRITERIA
Unless subject is enrolled as a patient, subjects should not have current Axis I psychiatric disorders as identified with the Structured Clinical Interview for DSM-IV, non-patient edition (SCID/NP)
If a healthy volunteer, past bipolar depression and any history of psychosis or delusional disorders
If a healthy volunteer, first degree relative with history of psychotic disorder such as schizophrenia or bipolar disorder
If a healthy volunteer, psychotropic medication within 4 weeks of scanning
Medications that act on the central nervous system (e.g., Lorazepam, Codeine) and thus may interfere with the interpretation of study results. Specific exclusionary drug classes include but are not limited to: (opioid analgesics, DA receptor agonists, anticholinergics, MAO inhibitors, COMT inhibitors, as well as any illicit substances). In addition, healthy participants may not be on psychotropic medications
Pregnancy, i.e., a positive Beta-HCG urine test conducted prior to each experiment session
Current or past history of cubital tunnel syndrome or carpal tunnel syndrome for shock studies that use the wrist for placement of electrodes. Cubital tunnel and carpal tunnel syndrome are exclusionary only for diagnosis on same arm as electrodes and are not exclusionary for studies that place shocks on ankles or feet
Reynauds syndrome for the cold pressor test experiment
Color blindness (for the active avoidance task only)
ADDITIONAL EXCLUSION CRITERIA FOR PATIENTS
Patients who would be unable to comply with study procedures or assessments
Patients will be excluded if they have a current or past history of any
psychotic disorder, bipolar disorder, delirium, dementia, amnestic disorder
cognitive disorder not otherwise specified, any of the pervasive developmental
disorders, or mental retardation
Patients (except PTSD) on psychotrophic medications within 2 wees of study
visits, or within 6 weeks of study visits for fluoxetine will be excluded
PTSD patients on psychotropics medication within 2 weeks of study visits will
be excluded, with the exception of antidepressants, and benzodiazepines; the
preceding two classes of medications will not preclude enrollment for PTSD
participants only
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note